1. GPCR/G Protein
    Metabolic Enzyme/Protease
  2. Angiotensin Receptor
  3. LCZ696

LCZ696 (Synonyms: Sacubitril mixture with Valsartan)

Cat. No.: HY-18204A Purity: 99.99% ee.: 99.99%
Handling Instructions

LCZ696 (Sacubitril mixture with Valsartan), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting angiotensin receptor-neprilysin (NEP) inhibitor for hypertension and heart failure.

For research use only. We do not sell to patients.

LCZ696 Chemical Structure

LCZ696 Chemical Structure

CAS No. : 936623-90-4

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in Water USD 105 In-stock
Estimated Time of Arrival: December 31
5 mg USD 70 In-stock
Estimated Time of Arrival: December 31
10 mg USD 100 In-stock
Estimated Time of Arrival: December 31
50 mg USD 190 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of LCZ696:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review


LCZ696 (Sacubitril mixture with Valsartan), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting angiotensin receptor-neprilysin (NEP) inhibitor for hypertension and heart failure[1][2].

IC50 & Target

Angiotensin receptor-neprilysin[1]

In Vitro

LCZ696 (Sacubitril mixture with Valsartan) significantly augments the inhibition of cardiac myocyte hypertrophy and collagen accumulation by valsartan[2].

In Vivo

LCZ696 (Sacubitril mixture with Valsartan) exerts a blood pressure lowering effect. Blood pressure reduction by LCZ696 is associated with a significant increase in urinary sodium excretion and sympathetic activity suppression. LCZ696 significantly ameliorates cardiac hypertrophy and inflammation, coronary arterial remodeling, and vascular endothelial dysfunction in high-salt loaded SHRcp compared with valsartan[3].
Pre-treatment with LCZ696 (Sacubitril mixture with Valsartan) reduces the ischemic area. The decrease in cerebral blood flow in the peripheral region of the ischemic area is significantly attenuated by pre-treatment with LCZ696. LCZ696 pre-treatment significantly decreases the increase of superoxide anion production in the cortex on the ischemic side[4].

Clinical Trial
Molecular Weight







O=C(CCC([O-])=O)N([[email protected]](CC(C=C1)=CC=C1C2=CC=CC=C2)C[[email protected]@H](C)C(OCC)=O)[H].[O-]C([[email protected]@H](N(C(CCCC)=O)CC3=CC=C(C4=CC=CC=C4C5=NN=N[N-]5)C=C3)C(C)C)=O.[Na+].[Na+].[Na+].[2.5H2O]


Room temperature in continental US; may vary elsewhere

Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (104.39 mM)

H2O : ≥ 50 mg/mL (52.19 mM)

*"≥" means soluble, but saturation unknown.

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.0439 mL 5.2193 mL 10.4385 mL
5 mM 0.2088 mL 1.0439 mL 2.0877 mL
10 mM 0.1044 mL 0.5219 mL 1.0439 mL
*Please refer to the solubility information to select the appropriate solvent.
Animal Administration

Rats: LCZ696 or valsartan is orally administered as a powder in gelatin mini-capsules at the beginning of the dark period once daily. The vehicle group rats are given empty capsules. Miniature telemetry devices are implanted into 12 or 13-week-old SHRs. BP and heart rate variability, low frequency power of systolic BP, and spontaneous baroreceptor reflex gain are monitored during the dark and light periods. The SHRs are divided into 3 groups at 16 weeks of age: (i) vehicle, (ii) LCZ696, and (iii) valsartan. The dose of LCZ696 and valsartan is 20 and 10mg/kg/day from 16 to 18 weeks of age, respectively, and 60 and 30mg/kg/day from 18 to 23 weeks of age, respectively. At 21 weeks of age, the SHR diet is switched to a low-salt diet from a high-salt diet[1].

Mice: Mice are treated with VAL (3 mg/kg per day) or LCZ696 (6 mg/kg per day) orally as powder in gelatin mini-capsules daily for 2 weeks before MCA occlusion. Body weight is measured after VAL or LCZ696 pre-treatment for 2 weeks. Systolic blood pressure, diastolic blood pressure and heart rate are measured by telemetry at 10 weeks of age[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Purity: 99.99% ee.: 99.99%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country or Region *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: